UA96930C2 - Композиция замедленного действия, которая содержит глюкуронатную соль соединений пиперазина и ее применение - Google Patents
Композиция замедленного действия, которая содержит глюкуронатную соль соединений пиперазина и ее применениеInfo
- Publication number
- UA96930C2 UA96930C2 UAA200804633A UAA200804633A UA96930C2 UA 96930 C2 UA96930 C2 UA 96930C2 UA A200804633 A UAA200804633 A UA A200804633A UA A200804633 A UAA200804633 A UA A200804633A UA 96930 C2 UA96930 C2 UA 96930C2
- Authority
- UA
- Ukraine
- Prior art keywords
- disease
- sustained
- useful
- disorders
- release composition
- Prior art date
Links
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical class OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000004885 piperazines Chemical class 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 2
- 206010001497 Agitation Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010062767 Hypophysitis Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 102000003946 Prolactin Human genes 0.000 abstract 1
- 108010057464 Prolactin Proteins 0.000 abstract 1
- 208000012322 Raynaud phenomenon Diseases 0.000 abstract 1
- 206010039710 Scleroderma Diseases 0.000 abstract 1
- 206010041250 Social phobia Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 238000013019 agitation Methods 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 230000008855 peristalsis Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- -1 piperazine compound Chemical class 0.000 abstract 1
- 210000003635 pituitary gland Anatomy 0.000 abstract 1
- 229940097325 prolactin Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Это изобретение предлагает фармацевтические композиции, которые содержат соль глюкуроната соединения пиперазина, которая является полезным модулятором одного или нескольких GPCR.В частности, эта солевая форма и фармацевтически приемлемые композиции на ее основе излечивают или облегчают разнообразные болезни и расстройства, среди которых болезнь Паркинсона, психозы (например, шизофрения, маниакально-депрессивный психоз, острая депрессия и биполярные расстройства), депрессия, стресс и утомляемость, болезнь Альцгеймера, болезнь Гантингтона, панический синдром, синдром навязчивого состояния, расстройства питания, наркозависимость, социальные фобии, агрессивность или возбуждение, мигрень, склеродермия и болезнь Рейно, рвота, расстройства желудочно-кишечного тракта, связанные с регулированием перистальт�
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71606605P | 2005-09-12 | 2005-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA96930C2 true UA96930C2 (ru) | 2011-12-26 |
Family
ID=37865522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200804633A UA96930C2 (ru) | 2005-09-12 | 2006-09-12 | Композиция замедленного действия, которая содержит глюкуронатную соль соединений пиперазина и ее применение |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7709024B2 (ru) |
| EP (1) | EP1988904A2 (ru) |
| JP (1) | JP2009507923A (ru) |
| KR (1) | KR20080058384A (ru) |
| CN (1) | CN101262868B (ru) |
| AR (1) | AR055424A1 (ru) |
| AU (1) | AU2006291060B2 (ru) |
| BR (1) | BRPI0615670A2 (ru) |
| CA (1) | CA2621266A1 (ru) |
| EA (1) | EA200800820A1 (ru) |
| IL (1) | IL189821A0 (ru) |
| PE (1) | PE20070523A1 (ru) |
| TW (1) | TW200800306A (ru) |
| UA (1) | UA96930C2 (ru) |
| WO (1) | WO2007033193A2 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200600414A (es) * | 2005-09-12 | 2007-09-20 | Sal de glucuranato de compuesto de piperazine | |
| TW200800306A (en) | 2005-09-12 | 2008-01-01 | Wyeth Corp | Sustained-release formulation and uses thereof |
| GT200600416A (es) | 2005-09-12 | 2007-09-20 | Sales salicilato y gentisato de un compuesto de piperazina | |
| WO2012054815A1 (en) | 2010-10-22 | 2012-04-26 | Duke University | Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4438119A (en) | 1982-12-23 | 1984-03-20 | Mead Johnson & Company | Method for alleviation of extrapyramidal motor disorders |
| US4687772A (en) | 1986-10-07 | 1987-08-18 | Bristol-Myers Company | Method for improvement of short term memory |
| US4771053A (en) | 1987-03-02 | 1988-09-13 | Bristol-Myers Company | Method for alleviation of primary depressive disorders |
| JPS6434920A (en) * | 1987-07-17 | 1989-02-06 | Warner Lambert Co | Therapy for mycobacterium abium intracellular complex infection |
| US5162375A (en) | 1988-05-06 | 1992-11-10 | Beecham Group P.L.C. | Treatment of neuronal degeneration with 5HT1A agonists |
| DE4135551A1 (de) | 1991-08-31 | 1993-03-04 | Schering Ag | Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen |
| US5824680A (en) | 1991-08-31 | 1998-10-20 | Bayer Aktiengesellschaft | Ipsapirone for the treatment of alzheimer's disease by improving memory |
| US5716960A (en) * | 1995-01-13 | 1998-02-10 | U.S. Bioscience Inc. And Individuals | Crystalline trimetrexate salts and the process for making the same |
| SE9900190D0 (sv) | 1999-01-22 | 1999-01-22 | Astra Ab | New compounds |
| HN1999000146A (es) | 1998-09-21 | 2000-11-11 | Pfizer Prod Inc | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas. |
| BR0013498A (pt) * | 1999-08-23 | 2002-05-14 | Solvay Pharm Bv | Composto, método para a preparação do mesmo, composição farmacêutica, e, métodos para a preparação da mesma e para o tratamento de distúrbios do snc |
| BR0107721A (pt) | 2000-01-19 | 2002-10-01 | Akzo Nobel Nv | Combinação, uso de mirtapazina e gepirona, método para o tratamento de depressão ou de um distúrbio relacionado em um indivìduo de uma espécie vertebrada, e, kit de paciente que contém meios para a administração de doses unitárias dosadas |
| AR032712A1 (es) * | 2001-02-21 | 2003-11-19 | Solvay Pharm Bv | Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen |
| EP1391199B1 (en) * | 2001-05-10 | 2008-12-10 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
| AU2004266233A1 (en) * | 2003-08-13 | 2005-03-03 | Amgen, Inc. | Melanin concentrating hormone receptor antagonist |
| CN1934108A (zh) | 2003-12-18 | 2007-03-21 | 特瓦制药工业有限公司 | 齐拉西酮碱的多晶型b2 |
| GT200600416A (es) | 2005-09-12 | 2007-09-20 | Sales salicilato y gentisato de un compuesto de piperazina | |
| TW200800306A (en) | 2005-09-12 | 2008-01-01 | Wyeth Corp | Sustained-release formulation and uses thereof |
| GT200600414A (es) | 2005-09-12 | 2007-09-20 | Sal de glucuranato de compuesto de piperazine |
-
2006
- 2006-09-11 TW TW095133455A patent/TW200800306A/zh unknown
- 2006-09-11 PE PE2006001089A patent/PE20070523A1/es not_active Application Discontinuation
- 2006-09-11 AR ARP060103946A patent/AR055424A1/es not_active Application Discontinuation
- 2006-09-12 EA EA200800820A patent/EA200800820A1/ru unknown
- 2006-09-12 EP EP06803442A patent/EP1988904A2/en not_active Withdrawn
- 2006-09-12 BR BRPI0615670-3A patent/BRPI0615670A2/pt not_active IP Right Cessation
- 2006-09-12 US US11/519,763 patent/US7709024B2/en not_active Expired - Fee Related
- 2006-09-12 JP JP2008531256A patent/JP2009507923A/ja active Pending
- 2006-09-12 CA CA002621266A patent/CA2621266A1/en not_active Abandoned
- 2006-09-12 AU AU2006291060A patent/AU2006291060B2/en not_active Ceased
- 2006-09-12 KR KR1020087008795A patent/KR20080058384A/ko not_active Ceased
- 2006-09-12 UA UAA200804633A patent/UA96930C2/ru unknown
- 2006-09-12 WO PCT/US2006/035520 patent/WO2007033193A2/en not_active Ceased
- 2006-09-12 CN CN2006800333732A patent/CN101262868B/zh not_active Expired - Fee Related
-
2008
- 2008-02-28 IL IL189821A patent/IL189821A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101262868A (zh) | 2008-09-10 |
| US20070059366A1 (en) | 2007-03-15 |
| IL189821A0 (en) | 2008-08-07 |
| AU2006291060B2 (en) | 2011-09-29 |
| PE20070523A1 (es) | 2007-06-28 |
| CA2621266A1 (en) | 2007-03-22 |
| EP1988904A2 (en) | 2008-11-12 |
| CN101262868B (zh) | 2011-01-12 |
| AU2006291060A1 (en) | 2007-03-22 |
| WO2007033193A2 (en) | 2007-03-22 |
| KR20080058384A (ko) | 2008-06-25 |
| HK1120408A1 (en) | 2009-04-03 |
| BRPI0615670A2 (pt) | 2011-05-24 |
| WO2007033193A3 (en) | 2007-09-20 |
| EA200800820A1 (ru) | 2008-08-29 |
| AR055424A1 (es) | 2007-08-22 |
| TW200800306A (en) | 2008-01-01 |
| JP2009507923A (ja) | 2009-02-26 |
| US7709024B2 (en) | 2010-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200505903A (en) | CGRP receptor antagonists | |
| IL182317A0 (en) | Cgrp receptor antagonists | |
| GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
| EP1796678A4 (en) | Carboxamide-spirolactam CGRP Receptor Antagonists | |
| MA35285B1 (fr) | Indazoles | |
| TN2009000095A1 (en) | Thiazole pyrazolopyrimidines as crf1 receptor antagonists | |
| DE602004026053D1 (ru) | ||
| TW200531689A (en) | Therapeutic agents | |
| TW200635903A (en) | Therapeutic agents | |
| MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
| TW200634016A (en) | Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors | |
| TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
| PT1984357E (pt) | Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes | |
| EA017914B8 (ru) | 1,4-ДВУЗАМЕЩЕННЫЕ 3-ЦИАНОПИРИДОНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЗИТИВНЫХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2 | |
| CY1107956T1 (el) | Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον | |
| TW200502221A (en) | Novel lactams and uses thereof | |
| EP1793827A4 (en) | TRICYCLIC ANILID SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | |
| GB0313612D0 (en) | Organic compounds | |
| IL194057A0 (en) | Pyrimidine, quinazoline, pteridine and triazine derivatives | |
| TW200745135A (en) | Therapeutic agents | |
| ZA200810031B (en) | 1,3-disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their use for the manufacture of medicaments | |
| TW200633986A (en) | Therapeutic agents | |
| TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
| IL195747A0 (en) | Pyrimidine and quinazoline derivatives as modulators of somatostatine receptor activity | |
| MX2009012518A (es) | Derivados de piperidina 4,4-disubstituidos. |